Robert John Motzer
Memorial Sloan Kettering Cancer Center · 1,642 works · 123,447 citations · h-index 148
Top works
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- Renal-Cell Carcinoma
- Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma
- Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma
- Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma
- Sunitinib in Patients With Metastatic Renal Cell Carcinoma
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- A POSTOPERATIVE PROGNOSTIC NOMOGRAM FOR RENAL CELL CARCINOMA
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
- SYSTEMIC THERAPY FOR RENAL CELL CARCINOMA
- Phase 3 trial of everolimus for metastatic renal cell carcinoma